https://www.sec.gov/ix?doc=/Archives/edgar/data/0001937993/000101376223005859/ea187126-8k_cadrenal.htm
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
October 20, 2023
Cadrenal Therapeutics, Inc.
822 A1A North, Suite 306
Ponte Vedra, Florida 32082
(904) 300-0701
Ticker CVKD
On October 20, 2023, Cadrenal Therapeutics, Inc. (the “Company”), held its 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) where the Company’s stockholders voted on the following two (2) proposals and cast their votes as described below. These matters are described in detail in the Company’s definitive proxy statement as filed with the Securities and Exchange Commission on August 28, 2023 (the “Proxy Statement”).
As of August 25, 2023, the record date of the 2023 Annual Meeting, there were 13,022,754 issued and outstanding shares of common stock entitled to vote at the 2023 Annual Meeting. Present in person or by proxy at the 2023 Annual Meeting were more than thirty-four percent (34%) of the issued and outstanding capital stock entitled to vote at the 2023 Annual Meeting, which constituted a quorum.
The final voting results from the 2023 Annual Meeting for Proposals No. 1 and 2, as described in the Proxy Statement, is set forth below.
Proposal 1. Election of Directors.
The following two (2) individuals were elected as Class I directors, to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified with the following votes:
Quang Pham
Glynn Wilson
Proposal 2. Ratification of the appointment of WithumSmith+Brown, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023.
The stockholders ratified and approved the appointment of WithumSmith+Brown, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023 based on the votes listed below:
Dated: October 23, 2023 CADRENAL THERAPEUTICS, INC. Quang Pham Chairman and Chief Executive Officer
Recent CVKD News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/12/2024 08:10:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 06/11/2024 09:27:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/11/2024 09:25:39 PM
- Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients • PR Newswire (US) • 06/03/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/29/2024 09:27:54 PM
- Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 • PR Newswire (US) • 05/23/2024 01:00:00 PM
- Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update • PR Newswire (US) • 05/09/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 10:23:10 AM
- Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 • PR Newswire (US) • 04/11/2024 08:30:00 PM
- Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts • PR Newswire (US) • 04/09/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 01:15:09 PM
- Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update • PR Newswire (US) • 03/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 10:24:44 PM
- Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference • PR Newswire (US) • 02/26/2024 02:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:49:23 PM
- Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial • PR Newswire (US) • 02/08/2024 02:00:00 PM
- Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions • PR Newswire (US) • 01/31/2024 02:00:00 PM
- Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 • PR Newswire (US) • 01/24/2024 02:00:00 PM
- Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference • PR Newswire (US) • 01/04/2024 02:00:00 PM
- Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target • PR Newswire (US) • 12/19/2023 02:00:00 PM
- Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization • PR Newswire (US) • 12/12/2023 02:00:00 PM
- Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023 • PR Newswire (US) • 11/30/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:15:30 PM
- Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update • PR Newswire (US) • 11/09/2023 02:00:00 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM